After completing the CME activity, learners should be better able to:

• Assess the evidence supporting a crucial role of the hedgehog signaling pathway in the pathophysiology of BCC and the effect of its inhibition on different aspects of cancer growth, progression and recurrence
• Evaluate the clinical trial data addressing the benefit /safety profile of approved and investigational inhibitors of the hedgehog signaling pathway for locally advanced or metastatic BCC
• Examine the integration of new targeted treatment options into the standard of care for BCC and strategies to optimize patients’ selection, dosing and duration of response

This activity is intended for medical oncologists, dermatologists and other healthcare professionals who treat patients with locally advanced or metastatic basal cell carcinoma.

There is no fee for this activity.

Please click here to register.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with locally advanced or metastatic basal cell carcinoma.

Credits:

1.0 ANCC Contact Hour(s)